RTP Mobile Logo
Oncology Today with Dr Neil Love: Advances in Endometrial Cancer (Audio Interview)
Released December 2021

Featuring an interview with Dr Matthew Powell. Published December 15, 2021. (Audio Interview)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.

    LEARNING OBJECTIVES

    • Describe the biologic rationale for, published research data with, and ongoing evaluation of immune checkpoint inhibitors in the management of endometrial cancer (EC), and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
    • Recognize the importance of microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) assessment for patients with EC, and adapt current testing practices to optimally identify these genetic abnormalities.
    • Recall the recent FDA approval of the anti-PD-1 antibody dostarlimab for recurrent or advanced dMMR EC, and identify individuals for whom treatment with this novel agent should be considered.
    • Consider the FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced EC that is not MSI high or dMMR who have experienced disease progression after prior systemic therapy; optimally integrate this novel regimen into current clinical management algorithms.
    • Design and implement a plan of care to manage side effects and toxicities associated with immune checkpoint inhibitor-based therapies for EC to support quality of life and continuation of therapy.
    • Review the mechanisms of action, emerging efficacy data and associated toxicities with novel immunotherapeutic agents and strategies under investigation for EC, and effectively prioritize clinical trial opportunities for eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Matthew A Powell, MD
    Professor, Department of Obstetrics and Gynecology
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Tesaro, A GSK Company, Seagen Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Eisai Inc.

    Release date: December 2021
    Expiration date: December 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):